Literature DB >> 6637762

Comparative study of the effect of slow channel inhibiting agents on ischemia-induced conduction delay as relevant to the genesis of ventricular fibrillation.

T Peter, T Fujimoto, H Hamamoto, W J Mandel.   

Abstract

Conduction delay has been shown to be an important factor in the genesis of ventricular fibrillation (VF). We evaluated the relationship between conduction delay and (1) initiation of VF and (2) the effects of Ca++ blockers on conduction delay in 41 dogs: eight control (nontreated, non-VF); nine ischemic VF; eight verapamil-treated (0.15 mg/kg bolus followed by 7.5 micrograms/kg/min); eight diltiazem-treated (20 micrograms/kg/min); and eight nifedipine-treated (0.1 mg/kg bolus). Propagation of electrically-induced premature impulses from the midmyocardial bipole of one transmural electrode was recorded at epicardial and endocardial bipoles of other electrodes before and 5, 15, and 30 minutes after coronary ligation. Conduction delay (i.e., conduction times compared to preligation levels) of VF, verapamil, diltiazem, and nifedipine groups were compared to control group in normal and in the center and border of ischemic zones in both base to apex (anterograde) and apex to base (retrograde) directions. Results showed that there was no change in conduction delay in the normal zone between control and VF groups or the treated groups, but both in the center and border of ischemic zone VF was quantitatively related to conduction delay and Ca++ blockers, except that nifedipine significantly reduced conduction delay. We conclude that our model provides a new approach to the assessment of anti-VF intervention. Further, verapamil and diltiazem appear to be useful agents in reducing the risk of ischemia-induced reentrant ventricular tachyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637762     DOI: 10.1016/0002-8703(83)90647-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia.

Authors:  Q Timour; B Bui-Xuan; G Faucon; J F Aupetit
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

2.  Antiarrhythmic effects of a benzothiazine derivative (SD-3211) and its stereoisomer (SA3212) in anaesthetized rats and isolated perfused rat hearts compared with bepridil.

Authors:  M Fukuchi; T Uematsu; S Nagashima; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

3.  Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II).

Authors:  J F Hansen
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  β-Adrenergic stimulation and rapid pacing mutually promote heterogeneous electrical failure and ventricular fibrillation in the globally ischemic heart.

Authors:  Vivek Garg; Tyson Taylor; Mark Warren; Paul Venable; Katie Sciuto; Junko Shibayama; Alexey Zaitsev
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-20       Impact factor: 4.733

5.  The Danish studies on verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

6.  Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension.

Authors:  J F Hansen
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Protection of rat atrial myocardium against electrical, mechanical and structural aspects of injury caused by exposure in vitro to conditions of simulated ischaemia.

Authors:  A M Northover; B J Northover
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

8.  Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem.

Authors:  J F Aupetit; Q Timour; G Chevrel; J Loufoua-Moundanga; S Omar; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.